NASDAQ · GENB
Generate Biomedicines, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GENB: Nov 5, 2026
Generate Biomedicines, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.5.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.50 | $-0.44 | $-0.55 | 3 |
| Dec 2026 | $-0.53 | $-0.44 | $-0.61 | 3 |
| Mar 2027 | $-0.55 | $-0.43 | $-0.63 | 3 |
| Jun 2027 | $-0.53 | $-0.41 | $-0.68 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · Fintel · BNK Invest- The Motley Fool · Oct 27, 3:05 PM EDTNvidia Plays Kingmaker Again. Why the Meta Deal Is a Winning Move.You can add Meta to the long list of AI stocks Nvidia has invested in.
- RTTNews · Aug 26, 4:33 AM EDTBiotech Stocks At 52-Week Highs – GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7%(RTTNews) – The following biotech stocks reached a 52-week high on August 25, 2026, driven by key catalysts including positive clinical trial results or the issuance of quarterly reports.
- RTTNews · Aug 25, 11:27 AM EDTGenerate Biomedicines Reports Q2 2026 Results; Advances Phase 3 Asthma Trial, Stock Up(RTTNews) – Generate Biomedicines Inc. (GENB), a clinical-stage generative biology company, recently reported second-quarter 2026 financial results and provided updates across its clinical pipeline and strategic collaborations.
- The Motley Fool · Aug 5, 11:50 AM EDTThis Is Nvidia CEO Jensen Huang's Favorite Biotech Stock — and You've Probably Never Heard of ItGenerate Biomedicines had its IPO this past February.
- RTTNews · Jul 14, 2:03 AM EDTEupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, announced several leadership changes within the company to support its upcoming planned phase of clinical and commercial growth.
- The Motley Fool · Jul 11, 11:57 AM EDTNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines.
- The Motley Fool · Jul 7, 11:27 AM EDTCathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on MondayCathie Wood added to her positions in Space Exploration, Bullish, and Generate Biomedicines on Monday.
- The Motley Fool · Jun 27, 7:43 AM EDTNvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion MarketArtificial intelligence technology giant Nvidia owns a handful of promising stocks.
- The Motley Fool · May 31, 4:37 PM EDTA New $21 Million Position Signals Confidence in This Post-IPO Drug DeveloperHarbourVest initiated 1,722,210 shares of Generate Biomedicines last quarter; the estimated trade size was $21.03 million based on quarterly average prices.
- Fintel · May 13, 11:56 PM EDTGenerate Biomedicines (GENB) Price Target Increased by 10.47% to 24.22The average one-year price target for Generate Biomedicines (NasdaqGS:GENB) has been revised to $24.22 / share. This is an increase of 10.47% from the prior estimate of $21.93 dated April 25, 2026. The price target is an average of many targets provided by ana
- BNK Invest · Mar 27, 2:18 PM EDTFriday's ETF Movers: SLVR, ARKGIn trading on Friday, the Sprott Silver Miners & Physical Silver ETF is outperforming other ETFs, up about 3.9% on the day. Components of that ETF showing particular strength include shares of New Pacific Metals, up about 6% and shares of Silvercorp Metals, up about 5.5% on
- The Motley Fool · Mar 3, 9:27 AM ESTCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtArk Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Generate Biomedicines, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.